T he primary objective of lung cancer screening with lowdose computed tomography (CT) is to detect early-stage lung cancer, thereby hopefully improving overall survival. A recent report from the National Lung Screening trial supports this hypothesis with a significant 20% reduction in lung cancer mortality among those screened with low-dose spiral CT compared to chest radiograph. 1 Minimally invasive thoracic surgery or video-assisted thoracic surgery (VATS) has evolved during the last two decades, and proved to have potential benefits compared to traditional thoracotomy in early-stage lung cancer. Several publications have demonstrated the safety and oncologic efficacy of VATS lobectomy in early-stage lung cancer . [2] [3] [4] Advantages reported for VATS lobectomy include reduced perioperative pain, [5] [6] [7] shorter hospital stay, 8 more rapid resumption of normal daily activities, 8 less impairment in pulmonary function postoperatively, 6, 7 less impairment in shoulder function, 9 reduced cytokine release, 6, 10 improved delivery of adjuvant chemotherapy, 11 lower incidence of complications, 12 and economical advantages. 13 The long-term survival seems to be equivalent to open surgery or even better. 14 Despite numerous publications addressing lung cancer CT screening only a few articles have been published addressing the surgical aspects and implications of early detection of lung cancer using CT screening. 15, 16 The relation between minimally invasive thoracic surgery and lung cancer CT screening has not yet been described in detail.
PATIENTS AND METHODS

Patients
The Danish Lung Cancer Screening trial (DLCST) included 4104 smokers and previous smokers enrolled from october 1, 2004 october 1, , to March 31, 2006 . Participants were randomized to either screening with five annual low-dose CT scans or no screening, as reported previously. 17 The study was funded in full by the Danish Ministry of Interior and Health, and performed in collaboration with the Dutch Belgian Randomised Lung Cancer Screening trial (NELSoN). 18 Participants were women and men, aged 50 to 70 years, without lung cancer related symptoms, and current or previous smokers with at least a 20 pack-year history. Previous smokers had to have quit after the age of 50 years and less than 10 years prior to the start of the study. Participants had to be able to climb two flights of stairs (36 steps) without a pause. Spirometry was performed annually in all participants and forced expiratory volume in 1 second had to be at least 30% of predicted normal at baseline to allow entry into the study.
Exclusion criteria were body weight more than 130 kg, previous treatment for lung cancer, breast cancer, malignant melanoma, or hypernephroma, in addition to a history of any other cancer within 5 years, tuberculosis within 2 years or any serious illness with a life expectancy less than 10 years. If applicants had had a CT scan of the chest within the last year, they were excluded.
The management algorithm for the screen-detected pulmonary nodules at baseline has been described previously. 17 At incidence screenings, nodules were characterized as new or preexisting, as solid, nonsolid, or part-solid in addition to the location, size, and shape. Size was assessed by linear measurement and volumetrics. Growth was evaluated by a calculation of volume doubling time (VDT). Categories of VDT were: less than 400 days, 400 to 600 days, and more than 600 days as also used in the NELSoN trial. 18 VDT less 400 days was regarded as suspicious of malignancy. In nonsolid nodules both linear growth and change in density (from nonsolid to part-solid) was used as criteria of malignancy. 19 Participants with nodules with a size less than 5 mm continued the planned annual CT screening. At baseline, nodules between 5 and 15 mm were followed with a CT scan after 3 months. If growth of more than 25% was detected, the participant was referred to diagnostic evaluation by a pulmonologist, as were those with nodules larger than 15 mm. 17 At the incidence rounds, patients with nodules with VDT less than 400 days were referred to the pulmonologist as were nonsolid nodules with growth and/or change to part-solid lesions.
When a clinical suspicion of lung cancer was made, all patients in the control arm followed the formalized Danish national guidelines. The guidelines are similar to those described by Lim et al. 20 The indication for surgical or oncologic intervention was decided by a multidisciplinary team of pulmonologists, radiologists, a pathologist, an oncologist, and a thoracic surgeon in all cases. 17 The data were prospectively registered in an institutional database.
CT-guided biopsy can be difficult in small nodules. When CT-guided biopsy was not feasible, we used VATS wedge resection and frozen section as diagnostic tools. In case of lung cancer, VATS lobectomy was performed in the same procedure.
All patients underwent a pulmonary-function test, bronchoscopy and, standard dose CT scan with contrast of the chest and upper abdomen. The mediastinum was further evaluated with endobronchial ultrasound, endo-esophageal ultrasound, or mediastinoscopy before pulmonary resection.
Positron emission tomography (PET) was used in participants with indeterminate nodules and as a staging procedure before surgery. PET and VDT predicted lung cancer independently of each other. Combining PET and VDT resulted in a sensitivity of 90% and a specificity of 82%. 21 Exclusion criteria for VATS lobectomy included tumor size larger than 6 cm, suspected chest-wall or diaphragm involvement, and centrally located tumors visible by bronchoscopy, possibly requiring sleeve resection or pneumonectomy. For patients with severe comorbidity, suspected N1 disease, former radiation, or for-mer thoracic surgery on the same side was not considered to be an exclusion criterion.
Surgical Procedures
For open operations a muscle-sparring posterolateral thoracotomy was performed. The VATS operations were performed using an anterior approach with two ports and a 5-cm utility incision, described in detail in a recent publication. 22 Patients were positioned in the lateral decubitus after double-lumen intubation for lung isolation. Two monitors were placed on each side of the table with the surgeon and the assistant positioned anterior to the patient. The scrub nurse was on the opposite side to the assistant. A 5-cm utility incision was performed just anterior to the edge of the latissimus dorsi muscle in the fourth intercostal space, splitting the serratus anterior muscle along the direction of its muscle fibers without using a rib retractor. A 30°C, 10-mm thoracoscope (Endoeye; olympus, Hamburg, Germany) was introduced and the thoracic cavity was evaluated with regard to unexpected pathology, adhesions, and the level of the diaphragm. Then, an additional 10-mm port was placed anterior at the level of the diaphragm used for the thoracoscope, and an additional 15-mm port posterior at the level of the diaphragm. Lobectomy was performed in a fashion similar to that of an open lobectomy with anatomical dissection of the hilum, but strictly based on monitor. The pulmonary vein, the bronchus, and the branches from the pulmonary artery were dissected individually and divided using an endoscopic-stapling device (endoGIA; Covidien plc, Norwalk, CT). The specimen was retrieved using an endoscopic bag. Systematic mediastinal lymph-node dissection was then performed, removing fatty tissue and lymph nodes from stations 2, 3, 4, 7, 8, and 9 on the right side and stations 5, 6, 7, 8, and 9 on the left side, according to the 7th edition of Tumor, Node, Metastasis (TNM) classification in lung cancer. 23 In case of conversion, the anterior incision was extended to an anterolateral thoracotomy.
Data Analysis
Data were expressed as number and percentage, mean and 95% confidence interval (CI), or median (range) when appropriate. Categorial values were analyzed by Fischer's exact test. Mann-Whitney U test was used for comparison of continuous variables. P values < 0.05 were considered statistically significant. operative mortality included patients who died within 30 days. 
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RESULTS
By February 1, 2011, i.e., approximately 1 year after the last screening scan, the screening arm of the DLCST revealed 77 suspicious nodules, 68 of which were lung cancer, one was a metastasis from a testis cancer, one was a lymphoma, and the remaining seven were benign.
Seventeen of the 68 patients with lung cancer had advanced disease and were referred for radiochemotherapy. The remaining 51 lung cancer patients were eligible for surgical treatment (Fig. 1) . Forty-nine operations were performed in 46 patients. Three patients underwent a second operation because of a new lung cancer discovered in the observation period. Two patients had a synchronous tumor in the other lobe on the same side, and it was treated in the same operation with a supplemental wedge resection.
Forty-one of 49 operations (84%) for lung cancer were performed by VATS (95% CI 70%-93%). Thirty-seven major VATS resections were performed, including one segmentectomy and 36 lobectomies. Four patients had a VATS wedge resection. In this study, lobectomy was considered the gold standard for the treatment of lung cancer, but three patients did not wish to have a lobectomy after the initial wedge resection. one patient had a synchronous tumor in the other lobe and two wedge resections were considered the best treatment for this patient.
There were only two patients presenting a ground glass opacity. Because ground glass opacity is known to be difficult to palpate, wide-wedge resection was performed by VATS, according to the localization on the CT scan.
Five patients had an open lobectomy. Three of these were suitable for VATS lobectomy, but there were no VATS surgeons available at the institution at the time. Furthermore, two intended VATS lobectomies were converted to open lobectomy. one patient had an open extended pneumonectomy because of locally advanced disease (Stage IIIa, T3N1M0).
In total, 58 operations were performed in the CT-screening arm, and in seven cases (12%, 95% CI 5%-23%) the final histology was benign. All seven patients with a benign nodule were treated with a VATS procedure. Six patients had a VATS wedge resection and one patient had a VATS lobectomy because of the central location of the nodule. The final diagnoses of the benign nodules were two hamartomas, two granulomas, and three fibrotic lymph nodes.
By February 1, 2011, 24 patients with lung cancer were detected in the control group. Sixteen (67%) of the 24 lung cancer cases were advanced disease and were referred for radiochemotherapy ( Fig. 1 ). Four (17%) had a VATS lobectomy, two (8%) had open lobectomy, and two (8%) had open pneumonectomy. The VATS rate in the control arm is 50%, (95% CI 16%-84%). In the CT-screened arm the VATS rate of 84% is significantly higher (p < 0.05).
Tumor stage of the lung cancers in the CT-screened arm and the control arm is shown in Table 1 according to the 7th edition of TNM classification in lung cancer. 20 Significantly more lung cancers were diagnosed in the screening group (68 versus 24, p < 0.001) and more were stage I (46 versus 5, p < 0.001). The number of stage-IV cancers was the same in both groups (6 versus 7; p > 0.05).
In the CT-screened arm, the tumor size in the thoracotomy group was 55(8-93) mm expressed as median and range as compared to the tumor size in VATS group 13(6-36) mm reflecting the selection before surgery. The tumor size of the benign or negative nodules was 10(10-38) mm versus 16(6-93) mm of the positive nodules, indicating that differentiation between benign and malignant disease is difficult in small lesions.
Complications to surgery in the CT-screened arm are listed in Table 2 , and the surgical outcome in the 37 major VATS resections are summarized in Table 3 . There was no 30-day mortality for the VATS resections, or for the open resections. However, after uneventful open lobectomy for a 12-mm adenocarcinoma, one patient was readmitted on day 25 with pneumonia, and he died of myocardial infarction with congestive heart failure on day 34.
DISCUSSION
The National Lung Screening trial recently announced the initial results of a large-scale trial of screening methods to reduce deaths from lung cancer by detecting cancers at relatively early stages. In a randomized trial involving more than 53,000 current and former heavy smokers, the effects of two screening procedures-low-dose helical CT and standard chest radiograph-on lung cancer mortality were compared. Twenty percent fewer lung cancer deaths were seen among those screened with low-dose spiral CT than those screened with chest radiograph. 1 The findings of this study are expected to increase the use of low-dose CT screening.
There are some concerns regarding a more widespread use of low-dose CT screening. First, the extent of overdiagnosis is an important issue. overdiagnosis bias refers to the screening-related detection of indolent or slow-growing tumors that would never have progressed to clinical disease during a person's lifetime, and thus would not have been diagnosed without screening. In the International Early Lung Cancer Action Programme (I ELCAB) a high proportion (81%) of bronchio-alveolar carcinoma (BAC) was found in stage-Ia adenocarcinomas with a subsequent 5-year survival of 100% for pure BAC and 95% for mixed BAC. 24 Next is the prevalence of false positive nodules. There can be psychological consequences of false positive test results. In this study, this has been evaluated by a questionnaire and will be published separately. 17 The screening regime used in this study is based primarily on the reports from the ELCAB [25] [26] [27] [28] and was later agreed upon by the European Union-United States Collaborative spiral CT working group under the International Association for the Study of Lung Cancer (IASLC). In addition, the regime was harmonized with the NELSoN trial 18 for pooling of results. Any screening aims at having a low rate of false positive findings, but high specificity usually implies low sensitivity with a need for a long follow-up. The frequency of surgical procedures for benign disease in CT-screening trials varies from 0% to 33% with an average of 18%. 29 In our series, seven of 58 operations (12%) were performed where the result was a benign lesion at final histology. In other series, many of these procedures were performed by a thoracotomy. 15, 16 All benign lesions in our series were performed by VATS, and fortunately there were no major complications to these procedures. The finding of suspicious small nodules creates a diagnostic challenge because CT-guided biopsy can be technically difficult in lesions smalller than 1 cm. In smaller nodules not eligible for CT-guided biopsy, we used a VATS wedge resection and an intraoperative frozen section in the same procedure as diagnostic tools. In case of lung cancer VATS, lobectomy was performed during the same procedure. Localizing small tumors deep in the lung parenchyma by VATS can be technically challenging. There are a few tricks that can be helpful doing this. Dividing the lower pulmonary ligament or dividing the hilar pleura can mobilize the lung to make bidigital palpation through the anterior utility incision possible. Furthermore, opening the fissure may aid in accessing tumors deep in the parenchyma, thus facilitating a VATS resection. In case of a very central tumor close to great vessels a diagnostic VATS lobectomy or VATS segmentectomy can be indicated.
In this study lobectomy was considered the gold standard for lung cancer patients with sufficient lung function. Segmentectomy might be an acceptable alternative in patients with a T1a tumor. 30 There are two large ongoing randomized trials that might add evidence to the question, but it will probably be 5 to 10 years before the data will be available. 31, 32 Bearing in mind the risk of overdiagnosis and given the nature of screening patients, who differ from an average patient in a thoracic surgical department, we find a minimally invasive approach of outmost importance in these patients. Although there is a lack of randomized controlled trials between open lobectomy and VATS lobectomy, there have been reported numerous benefits for patients in terms of reduced perioperative pain, [5] [6] [7] shorter hospital stay, 8 more rapid resumption of normal daily activities, 8 less impairment in pulmonary function postoperatively, 6,7 less impairment in shoulder function, 9 reduced cytokine release, 6,10 improved delivery of adjuvant chemotherapy, 11 lower incidence of complications, 12 and economical advantages. 13 Furthermore, the long-term survival seems to be equivalent to open surgery or even better. 14 The high percentage of lung resections by VATS (84%) and a VATS rate of 100% in the benign lesions in DLCST has not been reported previously in the literature. 15, 16 The surgical outcome was good and complications were few. We believe that it is of outmost importance for future low-dose CT-screening trials to have thoracic surgeons involved in the early-detection program, and that thoracic surgeons should have a dedicated VATS program. In this trial, the VATS surgeons were experienced before enrolling of patients. But there is a long learning curve in VATS major lung resections that should be taken into account. 33, 34 Despite expertise in VATS surgery, there is still a role for thoracotomy in tumors larger than 6 cm, central tumors requiring a bronchial or vascular sleeve resection, or in case of chest-wall involvement.
In conclusion, lung cancer screening seems to facilitate the use of minimally invasive thoracic surgery in the treatment of lung cancer with an 84% VATS rate in the CT-screening arm, which is significantly higher than that of the control arm (p < 0.05). All benign nodules could be removed by VATS without major complications. Thus, VATS seems to be a valuable tool in the diagnostic work up of screening detected lung cancer; and in our view, a basic requirement for a surgical institution involved in lung cancer screening is a dedicated VATS program.
